HOME > Business Wire > Article
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
TOKYO--( BUSINESS WIRE )-- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan.
Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu) have been working together to establish an infrastructure that enables the integrated production of pharmaceuticals, from active ingredients to final products, within Japan. With this approval, ARCALIS’s Minami-soma facilities and Meiji Seika Pharmatech Co., Ltd., a subsidiary of Meiji Seika Pharma, have been added as manufacturing sites. The technology transfer was managed and implemented by CSL Seqirus, the global licensor of KOSTAIVE®. As a result, domestically produced products, with active pharmaceutical ingredients manufactured at ARCALIS's Minami-soma facilities and formulated at Meiji Seika Pharmatech, are now able to be shipped for commercial use in Japan.
“We are pleased with the approval of domestic manufacturing sites in Japan for KOSTAIVE®,” said Dr. Pad Chivukula, COO of Arcturus Therapeutics. “As a joint venture partner with ARCALIS, Arcturus is delighted to support this effort through the continued transfer of our next-generation technologies, including LUNAR® lipid nanoparticle formulation processes and STARR® sa-mRNA drug substance manufacturing.”
About sa-mRNA
mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.
About Meiji Seika Pharma
Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs. ( https://www.meiji.com/global/pharmaceuticals/ )
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., founded in 2013, is a commercial mRNA Medicines and vaccines Company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. ( https://arcturusrx.com/ )
About CSL Seqirus
CSL Seqirus, a subsidiary of CSL Limited, is one of the world's largest suppliers of influenza vaccines. The company has state-of-the-art manufacturing facilities in the U.S., U.K., and Australia, and leading research and development capabilities. ( https://www.cslseqirus.com )
About ARCALIS
ARCALIS, Inc. is a joint venture company between Axcelead Inc. and Arcturus Therapeutics Inc., which owns a group of world-class drug-discovery and healthcare platform companies. The company provides drug discovery support, as well as a contract development and manufacturing business (CDMO business), for mRNA medicines and vaccines. ( https://corp.arcalis.co.jp/en )
View source version on businesswire.com: https://www.businesswire.com/news/home/20250131312981/en/
Contacts
Meiji Seika Pharma
Public Relations
Sayoko Taga
pr-pharma@meiji.com
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
Business Wire
-
02/18 15:50 Nihon Global Growth Partners Issues Presentation Highlighting the Sign...
-
02/18 09:00 3D Investment Partners Issues Open Letter to Sapporo’s Board of Dire...
-
02/18 05:00 Kyocera to Establish "O-RU Alliance" to Advance 5G Open RAN Deployment...
-
02/18 05:00 Kyocera Develops AI-powered 5G Virtualized Base Station for the Teleco...
-
02/18 02:10 Mitsubishi Electric Researcher Elevated to IEEE Fellow, Class of 2025
-
02/17 07:01 FPT Establishes FPT BTP Park to Enhance SAP Business in Japan
-
02/17 06:40 Mitsubishi Electric Signs Agreement with HD Renewable Energy, Will Est...
-
02/15 08:18 ispace Completes Success 5 of Mission 2 Milestones
-
02/14 23:50 U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltini...
-
02/14 14:25 AESC Ranks Fourth in 2024 Global Energy Storage Cell Shipments Accordi...
-
02/14 09:12 Kao Corporation Discloses the "Board of Directors' Opinion on Sharehol...
-
02/14 08:43 MUFG Bank, Ltd. announces Risk-Adjusted Capital Ratio Based on the Bas...
-
02/14 02:10 Mitsubishi Electric and CP Group Join Forces in Support of Increased S...
-
02/13 17:00 Nexon Releases Earnings for Fourth Quarter and Full-Year 2024
-
02/13 16:00 INFINITI at the 2025 Canadian International Auto Show
-
02/13 16:00 EXEO Group Selects Tonkean as Premier Process Automation and Orchestra...
-
02/13 13:36 Women Entrepreneurs from ASEAN and Japan Drive Innovation, Sustainabil...
-
02/13 12:00 Fonon Technologies to Bring Cutting-Edge Laser Tech to NCMS Sustainmen...
-
02/13 02:00 Kao: Bioré UV Partners with Stray Kids for an Exciting New Global Sun...
-
02/13 01:00 Yamaha Motor: Consolidated Business Results Summary ‐ Full Fiscal Ye...
-
02/13 00:00 Brightcove Appoints Takayuki Tadokoro As Country Manager of Brightcove...
-
02/12 12:00 SBC Medical Group Holdings Announces its Purchase of Bitcoin
-
02/12 09:57 MUFG Bank, Ltd. announces Consolidated Summary Report for the nine mon...
-
02/12 06:30 JT Group Recognized on CDP’s “Climate Change A List” For the 6th...
-
02/12 01:30 ONLYONE TRAVEL, a Pioneer in Unique Custom-Made Journeys, Raises 100 M...
-
02/11 14:05 Robotics Research: How Asia, Europe and America Invest – IFR Reports
-
02/11 14:02 LRN Research Unveils Key Gaps and Opportunities in Global Ethics and C...
-
02/11 14:00 Oracle Red Bull Racing and 1Password Upgrade Security in Multi-Year Pa...
-
02/11 11:00 Telecentro Argentina Expands Use of Netcracker Digital OSS and Critica...
-
02/10 22:00 Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUD...